EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis

Dae-Hwan Kim, Minjeong Sung, Myong-Suk Park, Eun-Gene Sun, Sumin Yoon, Kyung Hyun Yoo iD, Kamalakannan Radhakrishnan, Sung Yun Jung, Woo-Kyun Bae, Sang-Hee Cho, Ik-Joo Chung iD

Cancer Communications · 2024

DOI: 10.1002/cac2.12600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2024. Verfasst von Dae-Hwan Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology and Oncology, Chonnam National University Medical School, Hwasun, South Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bio & Medical Technology Development Program of the National Research Foundation, Korean Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Increased Galectin 3‐binding protein (LGALS3BP) serum levels have been used to assess hepatic fibrosis stages and the severity of hepatocellular carcinoma (HCC). Considering the crucial role of transforming growth factor‐β1 (TGF‐β1) in the emergence of these diseases, the present study tested the hypothesis that LGALS3BP regulates the TGF‐β1 signaling pathway.

Methods

The expression levels of LGALS3BP and TGFB1 were analyzed in patients with metabolic dysfunction‐associated steatohepatitis (MASH) and HCC. Multiple omics techniques, such as RNA‐sequencing, transposase‐accessible chromatin‐sequencing assay, and liquid chromatography‐tandem mass spectrometry proteomics, were used to identify the regulatory mechanisms for the LGALS3BP‐TGF‐β1 axis. The effects of altered TGF‐β1 signaling by LGALS3BP were investigated in conditional LGALS3BP ‐knockin and LGALS3BP ‐knockout mice.

Results

In patients with MASH and HCC, the levels of LGALS3BP and TGFB1 exhibited positive correlations. Stimulation of LGALS3BP by the inflammatory cytokine interferon α in HCC cells or ectopic overexpression of LGALS3BP in hepatocytes promoted the expression levels of TGFB1. Aggravated fibrosis was observed in the livers of hepatocyte‐specific LGALS3BP ‐knockin mice, with increased TGFB1 levels. LGALS3BP directly bound to and assembled integrin αV, an integral mediator required for releasing active TGF‐β1 from extracellular latent complex with the rearranged F‐actin cytoskeleton. The released TGF‐β1 activated JunB transcription factor, which in turn promoted the TGF‐β1 positive feedback loop. LGALS3BP deletion in the hepatocytes downregulated TGF‐β1 signaling and CCl 4 induced fibrosis. Moreover, LGALS3BP depletion hindered hepatocarcinogenesis by limiting the availability of fibrogenic TGF‐β1.

Conclusion

LGALS3BP plays a crucial role in hepatic fibrosis and carcinogenesis by controlling the TGF‐β1 signaling pathway, making it a promising therapeutic target in TGF‐β1‐related diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver CirrhosisLiver NeoplasmsAnimalsFemaleHumansMaleMiceAntigens, NeoplasmCarcinogenesisCarrier ProteinsMice, Inbred C57BLMice, KnockoutSignal TransductionTransforming Growth Factor beta1Extracellular Matrix Proteins

Stichwörter der Autor:innen

FAKF‐actinIntegrin αVInterferon αJunBLGALS3BPTGF‐β1hepatic carcinogenesismetabolic dysfuntion‐associated steatohepatitistensile force

Substanzen

Antigens, NeoplasmCarrier ProteinsTransforming Growth Factor beta1LGALS3BP protein, humanExtracellular Matrix ProteinsTGFB1 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology and Oncology, Chonnam National University Medical School, Hwasun, South Korea.
  • Department of Internal Medicine, Division of Hematology and Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
  • Combinatorial Tumor Immunotherapy MRC Center, Chonnam National University Medical School, Hwasun, South Korea.
  • National Immunotherapy Innovation Center, Hwasun, South Korea.
  • BioMedical Sciences Graduate Program, Chonnam National University, Hwasun, South Korea.
  • Department of Biological Science, Sookmyung Women's University, Seoul, South Korea.

ORCID-Profile: Kyung Hyun Yoo, Ik-Joo Chung

Förderung

  • Bio & Medical Technology Development Program of the National Research Foundation
  • Korean Government

Zitieren

APA

Kim, D. H., Sung, M., Park, M. S., Sun, E. G., Yoon, S., Yoo, K. H., Radhakrishnan, K., Jung, S. Y., Bae, W. K., Cho, S. H., & Chung, I. J. (2024). Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis. Cancer Communications. https://doi.org/10.1002/cac2.12600

Vancouver

Kim DH, Sung M, Park MS, Sun EG, Yoon S, Yoo KH, et al. Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis. Cancer Communications. 2024. doi:10.1002/cac2.12600

BibTeX
@article{Kim2024,
  author = {Kim, Dae-Hwan and Sung, Minjeong and Park, Myong-Suk and Sun, Eun-Gene and Yoon, Sumin and Yoo, Kyung Hyun and Radhakrishnan, Kamalakannan and Jung, Sung Yun and Bae, Woo-Kyun and Cho, Sang-Hee and Chung, Ik-Joo},
  title = {Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis},
  journal = {Cancer Communications},
  year = {2024},
  doi = {10.1002/cac2.12600}
}
Kostenlos starten →